• Markets
    • icon
  • Companies
CYP · ASX

Cynata Therapeutics Limited (ASX:CYP)

AU$0.12

 0.0 (0.0%)
ASX:Live
01/12/2023 03:58:51 PM
HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CYP Overview

CYP Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About CYP

Website

Cynata Therapeutics Limited

Telephone

61.3.7067.6940

Address

Level 3 100 Cubitt Street Cremorne, Victoria (VIC) 3121

Description

Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. It focuses on proprietary mesenchymal stem cell technology. The company was founded on March 12, 2003 and is headquartered in Carlton, Australia.

CYP Price Chart

Key Stats

Market Cap

AU$20.66M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.1 - 0.36

Trade Value (12mth)

AU$4,776.00

1 week

13.64%

1 month

-7.41%

YTD

-60.94%

1 year

-64.29%

All time high

4.60055

Key Fundamentals

EPS 3 yr Growth

183.600%

EBITDA Margin

N/A

Operating Cashflow

-$14m

Free Cash Flow Return

-70.20%

ROIC

-70.20%

Interest Coverage

N/A

Quick Ratio

7.50

Other Data

Shares on Issue (Fully Dilluted)

146m

HALO Sector

Healthcare

Next Company Report Date

21-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

CYP Announcements

Latest Announcements

Date Announcements

31 October 22

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

31 May 23

Application for quotation of securities - CYP

×

Application for quotation of securities - CYP

31 May 23

Cleansing Notice

×

Cleansing Notice

31 January 23

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

31 January 20

Cynata Investor Presentation

×

Cynata Investor Presentation

31 August 18

Cynata to Present at Rodman & Renshaw Investor Conference

×

Cynata to Present at Rodman & Renshaw Investor Conference

31 August 11

Eco Quest Limited - Appendix 4E and Annual Report 30 June 2011 (ECQ-AU)

×

Eco Quest Limited - Appendix 4E and Annual Report 30 June 2011 (ECQ-AU)

30 October 19

Cynata Corporate Presentation

×

Cynata Corporate Presentation

30 November 10

MD Presentation to AGM (ECQ-AU)

×

MD Presentation to AGM (ECQ-AU)

30 May 22

Cynata Adds New Site for MEND Clinical Trial

×

Cynata Adds New Site for MEND Clinical Trial

30 May 19

Cynata's Cymerus Technology Featured in ISCT Presentations

×

Cynata's Cymerus Technology Featured in ISCT Presentations

30 June 23

Cynata announces CEO succession and Board changes

×

Cynata announces CEO succession and Board changes

30 June 23

Proposed issue of securities - CYP

×

Proposed issue of securities - CYP

30 June 23

Notification regarding unquoted securities - CYP

×

Notification regarding unquoted securities - CYP

30 July 10

Corporate Presentation to Broker (ECQ-AU)

×

Corporate Presentation to Broker (ECQ-AU)

30 January 23

Cynata Receives IRB Approval for aGvHD Clinical Trial

×

Cynata Receives IRB Approval for aGvHD Clinical Trial

30 August 22

Appointment of Ms Janine Rolfe to the Cynata Board

×

Appointment of Ms Janine Rolfe to the Cynata Board

30 August 21

Appendix 4E & Annual Report

×

Appendix 4E & Annual Report

29 October 20

AusBiotech Conference Presentation

×

AusBiotech Conference Presentation

29 October 13

Eco Quest Limited - CEO Presentation to AGM (ECQ-AU)

×

Eco Quest Limited - CEO Presentation to AGM (ECQ-AU)

29 May 17

Cynata Investor Presentation May 2017

×

Cynata Investor Presentation May 2017

29 January 19

Clinical trial results to be presented at major symposium

×

Clinical trial results to be presented at major symposium

29 December 21

FUJIFILM Cellular Dynamics Executes Manufacturing Agreement

×

FUJIFILM Cellular Dynamics Executes Manufacturing Agreement

29 August 22

Preclinical study in coronary artery disease published

×

Preclinical study in coronary artery disease published

29 April 22

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

28 October 09

Annual Report to shareholders (ECQ-AU)

×

Annual Report to shareholders (ECQ-AU)

28 January 22

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

CYP Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.06 -0.04 -0.10 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.06 -0.04 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -70.0 35.6 -158.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.04 -0.03 -0.08 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.02 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -75.0 27.3 -152.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -7.8 -6.4 -78.8 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.20 0.17 0.09 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.18 0.15 0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock 52.4 -16.1 -46.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 130 143 145 Lock Lock Lock
Basic m Lock Lock Lock Lock 130 143 145 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 9 14 16 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.3 0.0 0.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -9 -7 -16 Lock Lock Lock
     Growth % Lock Lock Lock Lock 14.0 24.8 -145.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -9 -7 -17 Lock Lock Lock
     Growth % Lock Lock Lock Lock 13.6 24.0 -139.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -9 -6 -16 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -1 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -8 -5 -14 Lock Lock Lock
     Growth % Lock Lock Lock Lock -111.3 29.2 -162.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -5 -3 -14 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 18 0 7 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -5 -3 -14 Lock Lock Lock
     Growth % Lock Lock Lock Lock -52.4 36.1 -333.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 27 24 16 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 30 27 19 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -27 -24 -16 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 3 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 28 24 17 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 28 24 17 Lock Lock Lock
     Growth % Lock Lock Lock Lock 69.0 -15.6 -30.2 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -25.7 -20.5 -75.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -27.1 -22.7 -85.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -40.2 -26.4 -81.3 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -34.1 -20.8 -70.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -22.9 -12.6 -70.2 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 3.0 3.6 1.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -94.2 -99.3 -96.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 17.0 9.3 7.5 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 17.0 9.3 7.5 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 97.9 98.6 95.9 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -322.3 -127.4 -631.9 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -25.7 -20.5 -75.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -27.1 -22.7 -85.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -27.1 -22.7 -85.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 634.6 1,471.2 1,883.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -634.6 -1,471.2 -1,883.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CYP Shortsell

Frequently Asked Questions

The current share price of Cynata Therapeutics Limited (CYP:ASX) is AU$0.12.
The 52-week high share price for Cynata Therapeutics Limited (CYP:ASX) is AU$0.36.
The 52-week low share price for Cynata Therapeutics Limited (CYP:ASX)? is AU$0.10.
Cynata Therapeutics Limited (CYP:ASX) does not pay a dividend.
Cynata Therapeutics Limited (CYP:ASX) does not pay a dividend.
Cynata Therapeutics Limited (CYP:ASX) has a franking level of 0%.
Cynata Therapeutics Limited (CYP:ASX) is classified in the Healthcare.
The current P/E ratio for Cynata Therapeutics Limited (CYP:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.